No Data
【Brokerage Focus】China Merchants gives VIVA BIOTECH (01873) an initial "Strong Buy" rating, indicating that its CRO Orders are steadily recovering and that its performance is supported.
Jinwu Financial News | China Merchants issued a research report indicating that VIVA BIOTECH (01873) faced funding pressure due to the maturity buyback of Convertible Bonds in the early stage. After bringing in strategic investors like Temasek and Honghui in 2023, the company has fully redeemed its Convertible Bonds and will start fresh in 2024. The institution believes that the company's CRO Business is at the forefront of the FIC, "the spring water warms the duck first," clearly sensing the industry's recovery, and has early laid out AI to empower the entire research and development process; the CDMO is also well-coordinated with the CRO business, enhancing the flow. The institution points out that the company, as a global leader in the field of protein analysis, is leveraging its unique advantages in the SBDD field to build.
VIVA BIOTECH expects to report a profit warning, anticipating a Net income of approximately 0.15 billion to 0.18 billion yuan for the fiscal year 2024.
VIVA BIOTECH (01873) announced that, compared to a net loss of 99.8 million yuan for the year ending December 31, 2023, and a shareholder's net loss of 0.1161 billion yuan for the 2023 fiscal year, the group expects to achieve a turnaround and report a net income between 0.21 billion yuan and 0.24 billion yuan for the year ending December 31, 2024, with net income attributable to shareholders expected to be between 0.15 billion yuan and 0.18 billion yuan. The group anticipates that for this fiscal year, the adjusted net income according to non-International Financial Reporting Standards and net income attributable to shareholders (after deducting one-time reorganization expenses, properties, plants, and equipment
Viva Biotech Substantial Growth in Contract Research Business Supported Results >1873.HK
Viva Biotech Sees 2024 Net CNY150.0M-Net CNY180.0M >1873.HK
Viva Biotech Expects to Swing to Profit for 2024 >1873.HK
VIVA BIOTECH (01873.HK) expects to turn a profit for the year.
Gelonghui reported on March 13 that VIVA BIOTECH (01873.HK) announced that compared to a net loss of 99.8 million yuan in the previous year and a net loss attributable to shareholders of 116.1 million yuan for the 2023 fiscal year, the group expects to turn a profit by the end of the fiscal year on December 31, 2024, with net income ranging between 210 million yuan and 240 million yuan, and net income attributable to shareholders ranging between 150 million yuan and 180 million yuan. The group anticipates an adjusted net income and net income attributable to shareholders (after deducting one-time restructuring expenses and properties,
